Technetium (Tc) Labeled Radiopharmaceuticals Practice Test

In intravenous administration of Tc DTPA (Technetium-99m Diethylenetriaminepentaacetic Acid), the organs that typically receive varying doses can be influenced by the biodistribution of the radiopharmaceutical. The kidneys are particularly significant in the clearance and distribution of Tc DTPA because this compound is primarily used to evaluate renal function.

After administration, Tc DTPA is rapidly filtered by the kidneys and excreted into the urine. As a result, the kidneys receive the highest radiation dose due to their role in the uptake and elimination of this agent. The high dose to the kidneys is important for imaging purposes, as it allows for effective visualization of renal function and urinary tract assessment, which is one of the primary clinical applications of this radiopharmaceutical.

While the bladder does receive a considerable amount of radioactivity due to the collected urine, the kidneys initially receive the highest dose because of the direct uptake of the radionuclide. Understanding the distribution pattern of radioisotopes like Tc DTPA is crucial for clinicians in both diagnostics and therapy, making knowledge about organ-specific doses essential in radiology and nuclear medicine practices.